Ruggedness of Visible Residue Limits for Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible Residue Limits for Cleaning Validation
The author tests the ruggedness of VRL viewing conditions and defines optimal viewing conditions.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 102-111

API versus excipient versus formulation determinations. VRL data were broken into API, excipient, and formulation categories and analyzed to determine VRL correlation between a formulation and its components. Earlier work (1) compared VRL of 12 formulations with VRLs of the formulation components. Logically, the VRL of the formulation would be the same as the lowest component VRL—this was the case in 7 of the 12 comparisons. In three of the cases, however, the formulation VRL was higher, and in the other two cases, it was lower than the component VRLs.

The more important comparison was between VRL of the formulation and its API. In a pilot plant, it is not practical to perform VRL on every development formulation because the formulation compositions continually evolve up to the final market formulation selection. In the VRL comparison of formulations against components, 9 of the 12 formulation VRLs were lower than the VRL of the respective API. In one case, they were equal, and in the remaining two the formulations, the VRL was higher. The data concluded that VRL of API is not a good indicator for VRL of a formulation.

The data, however, were generated during the original VRL work where the residue concentrations and observer variability were higher. The subsequent VRL work generated additional data with increased experience and refined technique. The data gap narrowed between the formulations and APIs. The final average VRL of the 64 formulations was 0.7 μg/cm2. Of the 113 API determinations, it was 1.0 μg/cm2. Average VRL of the 64 excipients tested to date was 1.6 μg/cm2, and data showed significant overlap among formulations, APIs, and excipients.


Figure 2: Visible-residue limit (VRL) distribution.
A t-test comparison of API and formulation VRL data in Figure 2 shows that data distributions were equivalent. The formulation VRL data, despite its lower average value, was not statistically different when compared with API VRL data. The expanded data set analysis demonstrates that VRL of API is a good indicator for VRL of a formulation. VRL of a development API can be determined and safely used as the VRL for the development formulations.

Multisite study


Table IV: Multisite visible-residue limit (VRL) data.
VRL data from the three sites are shown in Table IV. Data from the Hoddesdon facility was generally lower than data from the other sites. Data from the West Point facility was slightly higher, which correlated to smaller spot sizes and resulted in higher spot concentrations (see Table V). Observers in Hoddesdon and West Point typically detected the lowest or next-to-lowest residue level. Data from the Montréal site resulted in three VRLs that were higher than VRLs from other sites; observer variability at Montréal was also greater. Of the three higher levels, one was comparable with the established VRL, and the other two were higher. All three of the higher levels were still well below the adulteration limit of 4 μg/cm2. A review of observer data showed that, in all cases, the higher levels were based on one observer not detecting the residue. Otherwise, the data more closely agreed with that of the other sites.


Table V: Multisite residue concentration comparison.
Several factors led to variability in the multisite data. The sample solution concentrations, spot sizes, and the resulting residue concentrations influenced VRL determination. The Hoddesdon site's lowest residue level was lower than the other sites, explaining their overall lower VRL levels. Observer variability at the Montréal site was similar to the early West Point data; a single observer skewed the results compared with the other observers and sites.

Overall, VRL determination was comparable at all three sites, and the experimental variability from sample preparation and observer subjectivity posed no risk for a potential cleaning failure because all VRL values were well below the ARL. The study also highlighted the value of the VRL training program and the experience gained through ongoing visual equipment inspections.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here